The Journal of allergy and clinical immunology
-
J. Allergy Clin. Immunol. · Jan 2021
Clinical Trial Observational StudyIL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study.
Patients with coronavirus disaese 2019 (COVID-19) can develop a cytokine release syndrome that eventually leads to acute respiratory distress syndrome requiring invasive mechanical ventilation (IMV). Because IL-6 is a relevant cytokine in acute respiratory distress syndrome, the blockade of its receptor with tocilizumab (TCZ) could reduce mortality and/or morbidity in severe COVID-19. ⋯ Baseline IL-6 greater than 30 pg/mL predicts IMV requirement in patients with COVID-19 and contributes to establish an adequate indication for TCZ administration.